Share this article
Share this article
SUZHOU, China, Jan. 18, 2021 /PRNewswire/ Cure Genetics announced a collaboration with Boehringer Ingelheim to develop novel Adeno-Associated Virus (AAV) vectorsleveraging Cure Genetics proprietary VELP
TM platform to develop next-generation gene therapies. This new collaboration combines Boehringer Ingelheim s experience in disease biology and gene therapy development with Cure Genetics AAV expertise in library construction and highly efficient in vivo AAV screening. The aim is to provide potential new AAV serotypes for patients.
The clinical applications of existing AAV serotypes are limited by some of their features, such as low transduction efficiency, low tissue specificity and immunogenicity. Therefore, finding new AAV serotypes to overcome these challenges becomes critical for the majority, if not all, AAV-based gene therapies.